Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
orphan drug status
Biotech
FDA tags Editas' thalassemia cell therapy an orphan drug
Editas has picked up more regulatory privileges for its ex vivo gene-edited medicine, securing FDA orphan-drug designation in beta thalassemia.
Nick Paul Taylor
May 13, 2022 8:40am
AviadoBio gains orphan tag for one-dose dementia gene therapy
Apr 27, 2022 9:18am
Intellia's CRISPR cell therapy snags orphan drug tag in AML
Mar 9, 2022 4:15pm
Ovid's fragile X drug shows promise in phase 2
May 7, 2020 10:35am
Supernus adds epilepsy drug via $185M Biscayne buy
Sep 14, 2018 9:45am
Aeterna review, Allegro eye test and Ocugen orphan tag—News of Note
Aug 9, 2017 9:46am
